Results 41 to 50 of about 3,446,938 (405)

Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma.

New England Journal of Medicine, 2021
BACKGROUND Tezepelumab is a human monoclonal antibody that blocks thymic stromal lymphopoietin, an epithelial-cell-derived cytokine implicated in the pathogenesis of asthma.
A. Menzies-Gow, J. Corren, A. Bourdin, G. Chupp, E. Israel, M. Wechsler, C. Brightling, J. Griffiths, A. Hellqvist, K. Bowen, P. Kaur, G. Almqvist, S. Ponnarambil, G. Colice   +13 more
semanticscholar   +1 more source

Airway responses and inflammation in subjects with asthma after four days of repeated high-single-dose allergen challenge [PDF]

, 2012
Background: Both standard and low-dose allergen provocations are an established tool in asthma research to improve our understanding of the pathophysiological mechanism of allergic asthma.
Rose, Markus A., Schubert, Ralf, Schulze, Johannes, Voss, Sandra, Zielen, Stefan, Zissler, Ulrich   +5 more
core   +2 more sources

Is Bronchiectasis (BE) Properly Investigated in Patients with Severe Asthma? A Real-Life Report from Eight Italian Centers

Journal of Respiration, 2023
Introduction: Asthma and bronchiectasis are often partners in a complex but uneven relationship with asthma receiving more attention. The aim of this study is to describe how bronchiectasis is investigated in some Severe Asthma (SA) Centers, scattered ...
Giovanna Elisiana Carpagnano, Vitaliano Nicola Quaranta, Claudia Crimi, Pierachille Santus, Francesco Menzella, Corrado Pelaia, Giulia Scioscia, Cristiano Caruso, Elena Bargagli, Nicola Scichilone, Eva Polverino   +10 more
doaj   +1 more source

Feasibility of Discontinuing Biologics in Severe Asthma: An Algorithmic Approach

Journal of Asthma and Allergy, 2021
In severe asthma with type 2 (T2) inflammation, biologics targeting key mediators of T2 inflammation, including interleukin (IL)-5, IL-4/IL-13, and immunoglobulin (Ig)E, remarkably improve the management of severe asthma, providing new insights into the ...
K. Hamada, K. Oishi, Y. Murata, Tsunahiko Hirano, K. Matsunaga   +4 more
semanticscholar   +1 more source

Effect of Vitamin D3 Supplementation on Severe Asthma Exacerbations in Children With Asthma and Low Vitamin D Levels: The VDKA Randomized Clinical Trial.

Journal of the American Medical Association (JAMA), 2020
Importance Severe asthma exacerbations cause significant morbidity and costs. Whether vitamin D3 supplementation reduces severe childhood asthma exacerbations is unclear.
E. Forno, L. Bacharier, W. Phipatanakul, T. Guilbert, M. Cabana, K. Ross, R. Covar, J. Gern, F. Rosser, J. Blatter, S. Durrani, Yueh-Ying Han, S. Wisniewski, J. Celedón   +13 more
semanticscholar   +1 more source

Biological therapy for severe asthma

Asthma Research and Practice, 2021
Around 5–10% of the total asthmatic population suffer from severe or uncontrolled asthma, which is associated with increased mortality and hospitalization, increased health care burden and worse quality of life. In the last few years, new drugs have been
S. Dragonieri, G. E. Carpagnano
semanticscholar   +1 more source

Influence of chronic azithromycin treatment on the composition of the oropharyngeal microbial community in patients with severe asthma [PDF]

, 2017
Background: This study of the oropharyngeal microbiome complements the previously published AZIthromycin in Severe ASThma (AZISAST) clinical trial, where the use of azithromycin was assessed in subjects with exacerbationprone severe asthma.
Brusselle, Guy, Dauwe, Kenny, Deschaght, Pieter, Deschepper, Ellen, Joos, Guy, Jordens, Paul, Lopes dos Santos Santiago, Guido, Vaneechoutte, Dries, Vaneechoutte, Mario, Verhofstede, Chris   +9 more
core   +1 more source

Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline

European Respiratory Journal, 2019
This document provides clinical recommendations for the management of severe asthma. Comprehensive evidence syntheses, including meta-analyses, were performed to summarise all available evidence relevant to the European Respiratory Society/American ...
F. Holguin, J. Cardet, K. Chung, S. Diver, D. S. Ferreira, A. Fitzpatrick, M. Gaga, Liz Kellermeyer, S. Khurana, S. Knight, V. McDonald, R. Morgan, V. Ortega, D. Rigau, P. Subbarao, T. Tonia, I. Adcock, E. Bleecker, C. Brightling, L. Boulet, M. Cabana, M. Castro, P. Chanez, A. Custovic, R. Djukanović, U. Frey, B. Frankemölle, P. Gibson, D. Hamerlijnck, N. Jarjour, S. Konno, Huahao Shen, C. Vitary, A. Bush   +33 more
semanticscholar   +1 more source

Molecular Targets for Biological Therapies of Severe Asthma

Frontiers in Immunology, 2020
Asthma is a heterogeneous respiratory disease characterized by usually reversible bronchial obstruction, which is clinically expressed by different phenotypes driven by complex pathobiological mechanisms (endotypes).
C. Pelaia, C. Crimi, A. Vatrella, C. Tinello, R. Terracciano, G. Pelaia   +5 more
semanticscholar   +1 more source

Severe Asthma Toolkit: an online resource for multidisciplinary health professionals—needs assessment, development process and user analytics with survey feedback

BMJ Open, 2020
Objectives Severe asthma imposes a significant burden on individuals, families and the healthcare system. New treatment and management approaches are emerging as effective options for severe asthma.
Peter G Gibson, Vanessa M McDonald, Peter A B Wark, John W Upham, Bruce Thompson, Mark Hew, Guy B Marks, Steven Maltby, Helen K Reddel, Gregory G King, Vanessa L Clark, Louisa Owens, Stephen Oo, Alan L James   +13 more
doaj   +1 more source